Ackermans & Van Haaren NV (GB:0GYM) has released an update.
Ackermans & van Haaren (AvH) leads a EUR 60 million Series B financing round for Confo Therapeutics to support clinical trials and advance drug approvals for rare endocrine diseases and obesity. AvH commits EUR 15 million and gains a 6.2% initial shareholding, while Confo Therapeutics aims to use the funding to fast-track its development pipeline, including next-generation obesity drugs. The investment adds to AvH’s growing Life Science portfolio, with AvH’s representative joining Confo’s Board of Directors.
For further insights into GB:0GYM stock, check out TipRanks’ Stock Analysis page.
